Nucleic acid cargo

Nucleic acid cargo refers to the functional genetic material—including deoxyribonucleic acid (DNA), messenger RNA (mRNA), small interfering RNA (siRNA), and antisense oligonucleotides (ASOs)—that serves as the active pharmaceutical ingredient in gene and RNA-based therapies (Sahin et al., 2014, Nature Reviews Drug Discovery). Unlike traditional small molecule or protein-based drugs that target existing cellular machinery, nucleic acid cargo acts by providing the instructions for protein synthesis, silencing specific genes through the RNA interference pathway, or correcting genetic sequences via genome editing (Kulkarni et al., 2018, Nature Nanotechnology). This modality is particularly valuable for addressing "undruggable" targets where traditional inhibitors are ineffective, as it operates at the level of transcription or translation (Dammes & Peer, 2020, Pharmaceutics). The clinical utility of nucleic acid cargo is intrinsically linked to its delivery system, which must protect the polyanionic and fragile molecules from nuclease degradation and facilitate their entry into the cytoplasm or nucleus (Wadhwa et al., 2020, Pharmaceutics). While transformative for treating genetic disorders and infectious diseases, challenges remain regarding the potential for innate immune activation and the requirement for precise, tissue-specific delivery to avoid off-target toxicity (Kulkarni et al., 2018, Nature Nanotechnology).

Other names

Genetic payloadTherapeutic nucleic acidOligonucleotide cargoDNA/RNA payloadPolynucleotide cargo

Nucleic acid cargo functions through various mechanisms including RNA interference (RNAi) to silence genes, antisense inhibition to modulate splicing or degrade mRNA, and mRNA translation to produce therapeutic proteins or antigens (Sahin et al., 2014, Nature Reviews Drug Discovery). It can also involve DNA-mediated gene replacement or CRISPR-based genome editing to permanently alter the host genome (Kulkarni et al., 2018, Nature Nanotechnology).